Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines. by Clutton, G, Carpov, A, Parks, C, Dean, H, Montefiori, D, Hanke, T

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors by Zhang X, Richlak S, Nguyen HT, Wallace O, Morrow G, Caulfield M, Parks C

Evaluation of a replication-competent VSV-SIV vaccine candidate by Jurgens CK, Morrow G, Boggiano C, Panis M, Coleman J, Powell R, Yuan M, Kemelman M, Tamot N, Lopez M, Ouattara A, Iyer S, Backer M, Wright K, Domi A, Chiuchiolo M, King CR, Caulfield M, Parks C

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses by Hoffenberg S, Pond S, Carpov A, Wagner D, Wilson A, Powell R, Lindsay R, Arendt H, DeStefano J, Poignard P, Simek M, Fling S, Phogat S, Labranche C, Montefiori D, Burton D, Parks C, King C, Koff W, Caulfield M

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vec... by Hara, H, Hara, H, Hironaka, T, Inoue, M, Iida, A, Shu, T, Hasegawa, M, Nagai, Y, Falsey, A, Kamali, A, Anzala, O, Sanders, E, Karita, E, Mwananyanda, L, Vasan, S, Lombardo, A, Parks, C, Sayeed, E, Krebs, M, Cormier, E, Ackland, J, Price, M, Excler, J